Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 3Completed 1

Sponsor Class

OTHER 11NIH 4NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 141Mesothelioma, Malignant 49Mesothelioma 24Lung Neoplasms 18Unspecified Childhood Solid Tumor, Protocol Specific 15Carcinoma, Non-Small-Cell Lung 14Solitary Fibrous Tumor, Pleural 11Pancreatic Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Ovarian Neoplasms 9Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 7Stomach Neoplasms 7Colonic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Retinoblastoma 6Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Neoplasms 6Thymoma 5Salivary Gland Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Astrocytoma 5Urinary Bladder Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Neuroblastoma 4Neoplasm Metastasis 4

Interventions

Specimen Handling 3Biopsy 3X-Rays 2Magnetic Resonance Spectroscopy 2veliparib 1trastuzumab biosimilar HLX02 1pertuzumab 1irinotecan sucrosofate 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Ferrosoferric Oxide 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Malignant Solid Neoplasm × Other solid neoplasm × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT02631733 2025-02-10

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡